Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer

Technology appraisal guidance
Reference number: TA214
Published: 23 February 2011

TA214 Breast cancer - bevacizumab (in combination with a taxane): Appendix B proposal paper presented to the Institute's Guidance Executive

TA214 Breast cancer - bevacizumab (in combination with a taxane): Appendix B proposal paper presented to the Institute's Guidance Executive

TA214 Breast cancer - bevacizumab (in combination with a taxane): Appendix B proposal paper presented to the Institute's Guidance Executive
29 July 2013
(229.84 Kb 6 sec)

Adobe Acrobat reader required.

Adobe Acrobat reader required.

This page was last updated: 31 July 2013